|
WO2017064098A1
|
|
Products for treating psychogenic pain disorders
|
|
DE102014014354A1
|
|
Methylphenidate or a physiologically acceptable salt thereof for use in the treatment of anorexia nervosa
|
|
WO2012052169A2
|
|
Particulate pharmaceutical composition containing an opioid and an opioid antagonist
|
|
WO2011110344A1
|
|
Multi-particulate pharmaceutical formulation for colon absorption
|
|
WO2011066980A2
|
|
Oral dosage forms with reduced potential for drug abuse
|
|
DE102010048883A1
|
|
Use of buprenorphine for abuse protection in pharmaceutical compositions containing a opioid full-agonist
|
|
CA2759870A1
|
|
Particulate pharmaceutical composition with an opioid and an opioid antagonist
|
